XML 87 R76.htm IDEA: XBRL DOCUMENT
v3.23.3

FAIR VALUE - Narrative (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | ---
Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) Rate | Sep. 30, 2022 USD ($) | Jul. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Change in fair value of contingent consideration | $ (17,532) | $ 3,900 | $ (8,124) | $ 6,845 |  |
Short-term contingent consideration | 12,800 |  | 12,800 |  |  | $ 26,300
Long-term contingent consideration | 16,100 |  | 16,100 |  |  | 22,200
Derivative liability | 764 |  | 764 |  |  | 252
Recurring |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Short-term contingent consideration | 12,800 |  | 12,800 |  |  | 26,300
Long-term contingent consideration | 16,100 |  | 16,100 |  |  | 22,200
Derivative liability | 764 |  | 764 |  |  | 252
Level 3 |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Change in fair value of contingent consideration recorded within costs and expenses | 512 |  | 512 |  |  |
Level 3 | Recurring |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Short-term contingent consideration | 12,800 |  | 12,800 |  |  | 26,300
Long-term contingent consideration | 16,100 |  | 16,100 |  |  | 22,200
Derivative liability | 764 |  | 764 |  |  | 252
Level 2 |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Debt conversion option value | 41,800 |  | 41,800 |  |  | 92,500
Convertible notes, par value | 40,000 |  | 40,000 |  |  | 70,000
Level 2 | Recurring |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Short-term contingent consideration | 0 |  | 0 |  |  | 0
Long-term contingent consideration | 0 |  | 0 |  |  | 0
Derivative liability | $ 0 |  | $ 0 |  |  | 0
Revenue Volatility |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Contingent consideration, measurement input | 0.30 |  | 0.30 |  |  |
Discount Rate |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Contingent consideration, measurement input | 0.180 |  | 0.180 |  |  |
Discounted Cash Flow | Discount Rate |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Contingent consideration, measurement input | 0.085 |  | 0.085 |  |  |
Discounted Cash Flow | Credit Spread |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Contingent consideration, measurement input | 0.038 |  | 0.038 |  |  |
Spectrum Pharmaceuticals, Inc. |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Business acquisition, contingent consideration, per share, maximum (in dollars per share) | $ / shares |  |  |  |  | $ 0.20 |
Contingent consideration | $ 0 |  | $ 0 |  | $ 3,932 |
Change in fair value of contingent consideration | 3,900 |  | 3,900 |  |  |
INDOCIN |  |  |  |  |  |
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |  |  |  |  |  |
Contingent consideration | 28,900 |  | 28,900 |  |  | 48,500
Contingent payment consideration, future royalties covenant, product net sales (over) |  |  | $ 20,000 |  |  |
Contingent consideration, royalty percentage | Rate |  |  | 20.00% |  |  |
Short-term contingent consideration | 12,800 |  | $ 12,800 |  |  | 26,300
Long-term contingent consideration | $ 16,100 |  | $ 16,100 |  |  | $ 22,200

X
- Definition Business Acquisition, Contingent Consideration, Per Share, Maximum + References No definition available. + Details
Name: | asrt_BusinessAcquisitionContingentConsiderationPerShareMaximum
Namespace Prefix: | asrt_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Royalty Percentage + References No definition available. + Details
Name: | asrt_BusinessCombinationContingentConsiderationRoyaltyPercentage
Namespace Prefix: | asrt_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Disclosure, Contingent Consideration, Liability, Future Royalties, Minimum Product Net Sales + References No definition available. + Details
Name: | asrt_FairValueDisclosureContingentConsiderationLiabilityFutureRoyaltiesMinimumProductNetSales
Namespace Prefix: | asrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair Value Of Convertible Notes, Par Value + References No definition available. + Details
Name: | asrt_FairValueOfConvertibleNotesParValue
Namespace Prefix: | asrt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | asrt_ScheduleOfCashAndCashEquivalentsAndMarketableSecuritiesLineItems
Namespace Prefix: | asrt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph b -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph b -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + References No definition available. + Details
Name: | us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=asrt_SpectrumPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=asrt_INDOCINProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |